Coordinates: 32°30′6″N 35°59′39″E / 32.50167°N 35.99417°E / 32.50167; 35.99417King Abdullah University Hospital (Arabic: مُستشفى الملك المؤسس عبد الله الجامعي), often abbreviated KAUH, is a hospital in Ar Ramtha, Jordan. It is the largest medical structure in the north of the country, serving approximately one million inhabitants from Ramtha, Irbid, Ajloun, Jerash, and Mafraq governorates. It is also the teaching hospital affiliated with Jordan University of Science and Technology (JUST), located within the campus adjacent to the university's Medical Faculties Complex.The hospital is staffed with full-time physicians and surgeons who are faculty members of the JUST Faculty of Medicine, in addition to many others from the Ministry of Health, and the Royal Medical Services (RMS).The overall area of various hospital buildings is 95,583 m2, in addition to a double story car park of 9,000 m2 area. The hospital has a bed capacity of 750 which can be increased to 900 beds in an emergency situation. Structurally, the hospital is composed of a 15-story high-rise building, in which all hospital beds are located, and a 3-story low-rise buildings in which patient clinics, diagnostic and other services are located. The hospital is connected to various health science faculties via the ground floor of the low-rise building.During the COVID-19 pandemic, KAUH was designated by the Jordanian Ministry of Health as the main center for COVID-19 testing and isolation in the north of Jordan and one of 7 such centers in the country.
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract and represent a paradigm of precision oncology in which histopathology and molecular profiling directly inform diagnosis, prognosis, and therapeutic strategy. Arising from the interstitial cells of Cajal or their precursors, GISTs display a wide morphological spectrum, including spindle cell, epithelioid, mixed, and rare histologic variants, often requiring immunohistochemical confirmation with KIT (CD117), DOG1, and CD34. Molecular characterization reveals a limited but clinically decisive range of driver mutations, most commonly in KIT and PDGFRA, with additional subsets involving SDH deficiency, NF1 alterations, and rare mutations such as BRAF, KRAS, or NTRK fusions. These molecular signatures underpin distinct biological behaviors, prognostic categories, and therapeutic sensitivities. Risk stratification incorporates tumor size, mitotic rate, anatomical location, and tumor rupture to predict recurrence and guide adjuvant therapy decisions. Targeted tyrosine kinase inhibitors (TKIs) have transformed GIST management, with imatinib as the foundational first-line therapy and subsequent agents, sunitinib, regorafenib, avapritinib, and ripretinib, addressing primary or secondary resistance driven by diverse mutational patterns. Nevertheless, challenges persist, including imatinib-resistant PDGFRA D842V mutations, SDH-deficient tumors lacking actionable kinase alterations, and the emergence of polyclonal secondary resistance due to heterogeneous KIT adenosine triphosphate (ATP)-binding pocket or activation loop mutations. Emerging therapeutic directions include next-generation kinase inhibitors, heat shock protein inhibitors, immunotherapy, metabolic and epigenetic targeting, and biomarker-driven individualized treatment strategies. This review synthesizes contemporary advances in the histopathological, molecular, and therapeutic landscape of GISTs, emphasizing an integrated diagnostic approach and highlighting ongoing efforts to overcome therapeutic resistance and optimize personalized care.
Cribriform morular thyroid carcinoma (CMTC) is a rare neoplasm more common in young euthyroid females, usually associated with familial adenomatous polyposis (FAP) syndrome, but also presenting as sporadic cases. These tumors result from the activation of the WNT/β-catenin signaling pathway, usually through germline APC gene mutations in FAP-associated disease, while sporadic cases may exhibit somatic mutations in APC, CTNNB1, and AXIN1. Additional possible molecular events include somatic mutations in KRAS, PIK3CA, KMT2C, KMT2D, TERT promoter or RET rearrangements. BRAF mutations do not occur. We describe a sporadic case of high-grade CMTC presented in a 44-year-old female with a large multilobulated, unifocal mass in the right thyroid lobe. The tumor showed the typical cribriform and morular patterns, high grade features (Ki-67 proliferative index of 20
Aneurysmal subarachnoid hemorrhage (aSAH) in infants is exceptionally rare, posing unique diagnostic and therapeutic challenges due to nonspecific clinical features and lack of standardized management protocols. We report a 6-month-old male presenting with vomiting, decreased consciousness, and seizures. Neuroimaging revealed diffuse subarachnoid hemorrhage from a ruptured left middle cerebral artery (MCA) aneurysm. Despite aggressive stabilization, the patient suffered rebleeding and succumbed to catastrophic complications. A systematic review following PRISMA guidelines was conducted (CRD420251145008). PubMed, Embase, and Cochrane CENTRAL were searched (2005–2025) for aSAH cases in infants ≤ 12 months. Extracted individual patient data were combined into a pooled individual–level analysis comparing survival and functional outcomes between intervention (endovascular/microsurgical) and conservative management using Fisher’s exact test. Sixty cases were identified (median age 6 months; 56
INTRODUCTION:Cardiovascular conditions significantly impact individuals' functional abilities. Existing evidence is limited on levels of occupational performance in individuals with cardiovascular conditions and what daily life activities are impacted. This study aimed to investigate occupational performance and quality of life in this population. METHODS:This current study utilized a cross-sectional design and convenient sampling. The sample consisted of 52 individuals with cardiovascular conditions. Instruments included Demographic and Health Condition Questionnaire, The Canadian Occupational Performance Measure (COPM), and The World Health Organization Quality of Life-BREF (WHOQOL-BREF). Data analyses included descriptive statistics, analysis of frequencies, Spearman rank-order correlations, and exploratory multivariable linear regression analyses. FINDINGS:Individuals with cardiovascular conditions perceived their occupational performance and satisfaction in the lower moderate range (COPM Performance: mean = 4.74, SD±1.75, range 1-8; COPM Satisfaction: mean = 4.5, SD±2.04, range 1-10). Self-care was the most common domain with occupational performance challenges (66.2% of all reported problems). Functional mobility was the most frequently reported self-care problem. In the WHOQOL-BREF, the physical domain was the lowest (M = 50.17, SD ±18.4, Range = 0-88). Significant predictor of better occupational performance included having higher physical health-related QoL (R2 = 0.158, p = 0.005). Significant predictors of greater satisfaction with occupational performance included participation in sports and having a better psychological QoL (R2 = 0.232, p = 0.048). CONCLUSION:Occupational performance in daily life activities in individuals with cardiovascular conditions, and their quality of life are negatively impacted. Individualized interventions for this population should target daily life activities, especially self-care.
Most melanoma-associated mortality occurs during the metastatic phase, yet our understanding of its clinical characteristics and molecular drivers remains limited. A growing body of literature is actively studying metastatic organotropism of melanoma from both basic and clinical perspectives. The active investigation of such phenomenon augments the risk stratification of patients and helps in the development of novel therapeutic approaches. In this investigation, we explore the clinicogenomic profile of pulmonary metastases of melanoma, an understudied challenging clinical entity. In this retrospective study, 1,142 melanoma patients who underwent next-generation sequencing of their tumors were included in the analyses. Patients were categorized based on the presence (n = 460) or absence (n = 682) of lung metastases. A comparative analysis between the study groups in terms of demographics, disease characteristics, and genomic profiles was conducted. The latter comparison utilized candidate genes originating from differential abundance analysis based on lung metastases status and overall survival (OS). Binary and Cox regression models were performed to identify possible associative and prognostic factors, respectively. The lung metastases sub-cohort had a mean age of 63.07 ± 14.3 years and was predominantly male (n = 292, 63.5
